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Abstract
Introduction: Acquired tamoxifen resistance involves complex signaling events that are not yet fully understood.
Successful therapeutic intervention to delay the onset of hormone resistance depends critically on mechanistic
elucidation of viable molecular targets associated with hormone resistance. This study was undertaken to
investigate the global proteomic alterations in a tamoxifen resistant MCF-7 breast cancer cell line obtained by long
term treatment of the wild type MCF-7 cell line with 4-hydroxytamoxifen (4-OH Tam).
Methods: We cultured MCF-7 cells with 4-OH Tam over a period of 12 months to obtain the resistant cell line. A
gel-free, quantitative proteomic method was used to identify and quantify the proteome of the resistant cell line.
Nano-flow high-performance liquid chromatography coupled to high resolution Fourier transform mass
spectrometry was used to analyze fractionated peptide mixtures that were isobarically labeled from the resistant
and control cell lysates. Real time quantitative PCR and Western blots were used to verify selected proteomic
changes. Lentiviral vector transduction was used to generate MCF-7 cells stably expressing S100P. Online pathway
analysis was performed to assess proteomic signatures in tamoxifen resistance. Survival analysis was done to
evaluate clinical relevance of altered proteomic expressions.
Results: Quantitative proteomic analysis revealed a wide breadth of signaling events during transition to acquired
tamoxifen resistance. A total of 629 proteins were found significantly changed with 364 up-regulated and 265
down-regulated. Collectively, these changes demonstrated the suppressed state of estrogen receptor (ER) and ER-
regulated genes, activated survival signaling and increased migratory capacity of the resistant cell line. The protein
S100P was found to play a critical role in conferring tamoxifen resistance and enhanced cell motility.
Conclusions: Our data demonstrate that the adaptive changes in the proteome of tamoxifen resistant breast
cancer cells are characterized by down-regulated ER signaling, activation of alternative survival pathways, and
enhanced cell motility through regulation of the actin cytoskeleton dynamics. Evidence also emerged that S100P
mediates acquired tamoxifen resistance and migration capacity.
Introduction
Acquired resistance to hormone therapy remains a major
challenge in the treatment of estrogen receptor positive
(ER(+)) metastatic breast cancers. Previous studies have
demonstrated that ER (+) breast cancer can escape anti-
estrogen actions by up-regulating other signaling
pathways involved in cell survival and proliferation.
Enhanced signaling via growth factor receptors, such as
EGFR [1] and HER2 [2], has been implicated in acquired
resistance to endocrine therapy. Activation of down-
stream intracellular signaling like the MAPK pathway
and the PI3K/Akt pathway has also been linked to hor-
mone resistance [3,4]. The cross-talk between ER and
such alternative signaling pathways are believed to enable
breast cancer to evade the antiproliferative effects of anti-
estrogens [5]. This knowledge has led to numerous
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treatment strategies combining endocrine and targeted
inhibitor therapies. However, early clinical trials of
EGFR- and ERBB2-targeted inhibitors (for example, gefi-
tinib, erlotinib, trastuzamab, and lapatinib) or m-TOR
inhibitors (everolimus and temsirolimus) in combination
with endocrine therapies have yielded mixed results
[6-8]. It is likely that cross-talk and negative feedback
loops may result in cellular resistance to individual inhi-
bitors [9]. Additional therapies targeting converging
points of shared signaling pathways, such as MYC and
cyclin D1-CKD4, may be more effective at blocking pro-
liferation in resistant breast cancers [10].
Current understanding of endocrine resistance
mechanisms is largely based on the study of relatively few
genes. Integrative approaches that examine gene expres-
sion in the genomic and proteomic context may lead to
the discovery of previously unconsidered mechanisms for
the modulation of therapeutic responses. The current
study employed a quantitative proteomic strategy to cap-
ture global changes in protein expression in a tamoxifen
resistant cell line derived from the wild type MCF-7 par-
ental cells. In vitro studies of tamoxifen resistance have
provided valuable foundational data that can be trans-
lated into in vivo and clinical applications [11-13]. The
most widely used and best characterized cell line for
study of acquired tamoxifen resistance has been the
MCF-7 variants, from which much of our current under-
standing of the mechanisms of hormone resistance has
derived [13,14]. While numerous earlier studies in other
laboratories have demonstrated that tamoxifen resistant
breast cancer cell lines were generated by long term
exposure of MCF-7 cells to 10-6 to 10-7M 4-OH Tam
over a period of 6 to 12 months, adaptive signatures of
the resulting resistant phenotypes may vary with different
experimental conditions employed. For example, EGFR
expression was reported to be 10-fold higher in one
tamoxifen-resistant model [14] but not in other models
[15,16]. It has also been shown [13] that use of dextran
coated charcoal-stripped (DCC) serum in tamoxifen
treatment may introduce, in addition to adaptive changes
of the cells in response to tamoxifen, effects of long term
estrogen deprivation (LTED), thus complicating the
interpretation of molecular signals of resistance develop-
ment for tamoxifen. Moreover, in estrogen deprived
medium, tamoxifen can act as an agonist [17] towards
ER, adding another complicating factor to the mechanis-
tic interpretation of tamoxifen resistance. We used a phe-
nol-red free DMEM medium containing 5% FBS so that
the background estrogen level is in a range that is unli-
kely to induce adaptive changes due to estrogen depriva-
tion and to minimize the agonistic action of tamoxifen in
ER(+) breast cancer cells.
In this study, we examined global proteomic altera-
tions of the tamoxifen resistant cell line vs the parental
MCF-7 cells using an isobaric labeling approach com-
bined with a high resolution tandem mass spectrometry
instrument for relative quantitative analysis. Our proteo-
mics data demonstrated extensive adaptive changes in
the proteome involving hundreds of significantly up-
and down-regulated proteins. In particular, results from
this study revealed the overexpression of multiple
tumorigenic, pro-metastatic proteins and the down-reg-
ulation of ER mediated signaling pathways. These find-
ings provide novel insights into the complex events of
the adaptive signaling network occurring during the
acquisition of tamoxifen resistance in breast cancer cells
and highlight the role of S100P in conferring both resis-
tance and enhanced migration.
Materials and methods
Cell culture
MCF-7 cell line was purchased from ATCC (ATCC
#HTB-22, Manassas, VA, USA), and routinely cultured in
phenol red-free DMEM medium supplemented with 5%
FBS, 4 mM glutamine, 1 mM sodium pyruvate, 100 IU/
mL penicillin, 100 μg/mL streptomycin and 0.25 μg/mL
amphotericin. Tamoxifen resistant variant cells (MCF-7-
TamR) derived from MCF-7 cells were continuously cul-
tured in the medium as described above containing addi-
tional 10-7 M 4-OH Tam (Sigma-Aldrich, St Louis, MO,
USA) for at least six months, along with the parental
MCF-7-cells under identical culture conditions except
that the control cells were treated with 0.1% ethanol. The
two cell lines were grown side by side at all times. Cul-
tures were maintained in 5% carbon dioxide at a tem-
perature of 37°C.
Cell growth assay
For growth assay in the presence of 10-7 M 4-OH Tam,
MCF-7 cells cultured with 10-7 M 4-OH Tam for zero to
six months were plated in six-well plates at a density of
50,000 in each well in 5% FBS DMEM medium. The cells
were then treated with 10-7 M 4-OH Tam for five days,
while equal treatment volumes of ethanol were used as a
vehicle control. Cell numbers were counted with a Coul-
ter instrument (Beckman-Coulter, Indianapolis, IN,
USA). The ratio of 4-OH Tam treated cell numbers to
vehicle treated cell numbers was defined as survival ratio.
Experiments were conducted in triplicate and data repre-
sented as mean ± SD.
For dose-dependent proliferation assays, MCF-7-TamR
and MCF-7-control cells were seeded in 96-well plate
with a density 3,000 per well and treated with varying
concentrations (10-7 to 10-5 M) of 4-OH tamoxifen for
five days; 0.1% ethanol was used as a vehicle control.
Alamar Blue dye (Invitrogen, Grand Island, NY, USA)
was added and incubated for 2 h at 37°C, protected
from light. A Synergy 2 microplate reader (BioTek,
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Winooski, VT, USA) was used to record fluorescence
using an excitation wavelength at 560 nm and emission
wavelength at 590 nm. The ratio of 4-OH Tam-treated
cell fluorescence intensity to that of vehicle treated cells
was determined as the survival ratios in triplicate experi-
ments. Data were represented as mean ± SD.
Colony formation assay
Colony formation assays were conducted as outlined pre-
viously [18-20]. MCF-7-control or MCF-7-TamR cells
were cultured in 5% FBS phenol red-free DMEM. Cells
were then plated at a density of 2,000 cells per well in
2 ml 5% FBS DMEM in six-well plates (Falcon, Franklin
Lakes, NJ, USA) and allowed to adhere overnight at 37°C,
5% CO2. The next day cells were treated with 4-OH Tam
(100 nM). Equal treatment volumes of dimethyl sulfoxide
(DMSO) were used as a vehicle control. Cells were allowed
to grow until control treatment colonies reached > 50 cells
per colony (approximately 10 to 14 days). Colonies were
then fixed with glutaraldehyde for 30 minutes, stained
with crystal violet (0.1% in 20% methanol) for 30 minutes
and washed. Colony number was determined manually.
Experiments were conducted in triplicate and data repre-
sented as mean ± SEM.
Cell lysis
MCF-7-TamR and MCF-7-control cells were cultured to
80% confluent in the medium as described above, and
washed with cold Hank’s Buffered Salt Solution (HBSS)
for three times, then collected with a cell scraper. NP40
cell lysis buffer (Invitrogen) containing additional 1 mM
of phenylmethylsulfonyl fluoride (PMSF) and protease
inhibitor cocktail (Sigma) was used to extract total cellu-
lar proteins. The concentration of proteins was mea-
sured with BCA assay (Pierce Biotechnology, Rockford,
IL, USA). The cell lysis was stored at -80°C before
further processing.
Trypsin digestion
Protein samples were digested with sequencing grade
modified trypsin (Promega Corp. Madison, WI, USA)
according to the manufacturer’s instructions. Briefly, to
aliquots of 100 μg of protein sample was added 45 μL of
200 mM triethyl ammonium bicarbonate (TEAB) and the
final volume was adjusted to 100 μL with ultrapure
water. A total of 5 μL of 200 mM tris(2-carboxyethyl)
phosphine (TCEP) was added and the resulting mixture
was incubated for 1 h, then 5 μL of 375 mM iodoaceta-
mide was added and the mixture was incubated for
30 minutes without light. After incubation, 1 mL of pre-
chilled acetone was added and the precipitation was
allowed to proceed overnight. The acetone-precipitated
protein pellets were suspended with 100 μL of 200 mM
TEAB and 2.5 μg of trypsin was added to digest the sam-
ple overnight at 37°C.
Tandem Mass Tags (TMT) labeling
Tandem mass tags TMT6 (Thermo Scientific, Rockford,
IL, USA) with different molecular weights (126 to
approximately 131 Da) were applied as isobaric tags for
relative and absolute quantification. According to the
manufacturer’s protocols, the digested samples were
individually labeled with TMT6 reagents for 1 h as fol-
lows: three 100-μg aliquots of digested MCF-7-control
peptides were each labeled with a different isobaric tag
(TMT126, 127 and 128, respectively). Likewise, 100-μg
aliquots of peptides from MCF-7-TamR cells were
labeled with TMT129, 130, and 131 mass tags, respec-
tively. The labeling reaction was quenched with 5%
hydroxylamine. Finally, the six labeled peptide aliquots
were combined for subsequent fractionation.
Fractionation of labeled peptide mixture using a strong
cation exchange column
The combined TMT labeled peptide mixture was frac-
tionated with a strong cation exchange column (SCX)
(Thermo Scientific) on a Shimadzu 2010 HPLC
equipped with a UV detector (Shimadzu, Columbus,
MD, USA). Mobile phase consists of buffer A (5 mM
KH2PO4, 25% acetonitrile, pH 2.8) and buffer B (buffer
A plus 350 mM KCl). The column was equilibrated with
Buffer A for 30 minutes before sample injection. The
mobile phase gradient was set as follows at a flow rate
of 1.0 mL/minute: (a) 0 to 10 minutes: 0% buffer B; (b)
10 to 40 minutes: 0% to 25% Buffer B, (c) 40 to 45 min-
utes: 25% to 100% Buffer B; (d) 45 to 50 minutes: 100%
buffer B; (e) 50 to 60 minutes: 100% to 0% buffer B; (f)
60 minutes to 90 minutes: 0% buffer B. A total of 60
fractions were initially collected, lyophilized and com-
bined into 15 final fractions based on SCX chromato-
graphic peaks.
Desalination of fractionated samples
A C18 solid-phase extraction (SPE) column (Hyper-Sep
SPE Columns, Thermo-Fisher Scientific, Waltham, MA,
USA) was used to desalt all collected fractions. The com-
bined 15 fractions were each adjusted to 1-mL final
volume containing 0.25% (v/v in water) trifluoroacetic acid
(TFA, Sigma). The C18 SPE columns were conditioned
before use by filling them with 1 mL acetonitrile and
allowing the solvent to pass through the column slowly
(approximately three minutes). The columns were then
rinsed three times with 1 mL 0.25% (v/v in water) TFA
solution. The fractions were loaded on to the top of the
SPE cartridge and allowed to elute slowly. Columns were
washed four times with 1-mL 0.25% TFA aliquots before
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the peptides were eluted with 3 × 400 μL of 80% acetoni-
trile/0.1% formic acid (aqueous).
LC-MS/MS analysis on LTQ-Orbitrap
Peptides were analyzed on an LTQ-Orbitrap XL instru-
ment (Thermo-Fisher Scientific) coupled to an Ultimate
3000 Dionex nanoflow LC system (Dionex, Sunnyvale,
CA, USA). High mass resolution was used for peptide
identification and high energy collision dissociation
(HCD) was employed for reporter ion quantification.
The RP-LC system consisted of a peptide Cap-Trap car-
tridge (0.5 × 2 mm) (Michrom BioResources, Auburn,
CA, USA) and a pre-packed BioBasic C18 PicoFrit analy-
tical column (75 μm i.d. × 15 cm length, New Objective,
Woburn, MA, USA) fitted with a FortisTip emitter tip.
Samples were loaded onto the trap cartridge and washed
with mobile phase A (98% H2O, 2% acetonitrile and
0.1% formic acid) for concentration and desalting. Sub-
sequently, peptides were eluted over 180 minutes from
the analytical column via the trap cartridge using a lin-
ear gradient of 6 to 100% mobile phase B (20% H2O,
80% acetonitrile and 0.1% formic acid) at a flow-rate of
0.3 μL/minute using the following gradient: 6% B for
5 minutes; 6 to 60% B for 125 minutes; 60 to 100% B
for 5 minutes; hold at 100% B for 5 minutes;100 to 6%
B in 2 minutes; hold at 6% B for 38 minutes.
The LTQ-Orbitrap tandem mass spectrometer was
operated in a data-dependent mode. Briefly, each full
MS scan (60,000 resolving power) was followed by six
MS/MS scans where the three most abundant molecular
ions were dynamically selected and fragmented by colli-
sion-induced dissociation (CID) using a normalized col-
lision energy of 35%, and the same three molecular ions
were also scanned three times by HCD-MS2 with colli-
sion energy of 45%. MS scans were acquired in profile
mode and MS/MS scans in centroid mode. LTQ-Orbi-
trap settings were as follows: spray voltage 2.0 kV,
1 microscan for MS1 scans at 60, 000 resolution (fwhm
at m/z 400), microscans for MS2 at 7,500 resolution
(fwhm at m/z 400); full MS mass range, m/z 400 to
1,400; MS/MS mass range, m/z 100 to 2,000. The “FT
master scan preview mode”, “Charge state screening”,
“Monoisotopic precursor selection”, and “Charge state
rejection” were enabled so that only the 2+, 3+ and 4+
ions were selected and fragmented by CID and HCD.
Database search and TMT quantification
The protein search algorithm used was Mascot (Matrix
Science, Boston, MA, USA). Mascot format files were
generated by the Proteome Discoverer 1.2 software
(Thermo-Fisher Scientific) using the following criteria:
database, IPI_Human.fasta.v3.77; enzyme, trypsin; maxi-
mum missed cleavages, 2; Static modifications, carbami-
domethylation (+57 Da), N-terminal TMT6plex (+229
Da), lysyl TMT6plex (+229 Da). Dynamic modifications,
N-terminal Cln- pyro-Glu(+17Da); methionine oxidation
(+16 Da); STY phosphorylation (+80 Da); MS peptide
tolerance was set at 15 ppm; MS/MS tolerance at
0.05 Da. Peptides reported by the search engine were
accepted only if they met the false discovery rate of P <
0.05 (target decoy database). For TMT quantification,
the ratios of TMT reporter ion abundances in MS/MS
spectra generated by HCD (up to six reporter ions ran-
ging from m/z 126.12 to m/z 131.14) from raw data sets
were used to calculate fold changes in proteins between
control and treatment.
Quantitative RT-PCR
Confirmation of selected targets identified in proteomic
analysis
Total RNA from MCF-7-TamR and control cells was
extracted using a PureLink total RNA purification system
(Invitrogen) and quantitatively analyzed with a nanodrop
spectrophotometer (Thermo Scientific). The reverse tran-
scription was carried out with a SuperScript first-strand
synthesis system (Invitrogen) using Oligo(dT)12-18 primers.
The primer pairs used to amplify the genes were designed
using the online tool of Oligo Perfect Designer (Invitro-
gen), and beta actin (actb) was employed as an internal
standard. Primer specificity was confirmed by BLAST ana-
lysis. For real-time PCR analyses, a MyiQ real time PCR
detection system (BioRad, Hercules, CA, USA) and a
SYBR GreenER qPCR supermix kit (Invitrogen) were used
as follows: 50°C for 2 minutes, 95°C for 8 minutes and 30
seconds, and 50 cycles (15 seconds at 95°C, 1 minute at
60°C). The data were analyzed with a normalized gene
expression method (ΔΔCt) using the iQ5 Optical System
Software (BioRad), and the gene actb was used as a refer-
ence for normalization. All experiments were repeated
three times independently.
ER regulated gene transcripts
MCF-7-control or MCF-7-TamR cells were seeded at a
density of 2 × 106 cells per 25 cm2 culture flask in
phenol red-free 5% FBS-DMEM. On the following day,
cells were washed in PBS and media were changed to
phenol red-free media supplemented with 5% CS-
DMEM and grown to 50 to 80% confluency for 48 h
before treatment with vehicle (DMSO), 17b-estradiol
(100 pM), or tamoxifen (100 nM). RNA was extracted
using QiaShredders (QIAGEN, Valencia, CA, USA)
and purified on RNeasy columns (QIAGEN) according
to the manufacturer’s protocol. RNA quality and con-
centration were determined by absorbance at 260 and
280 nm. Then 2 μg of total RNA was reverse tran-
scribed using the iScript kit (Bio-Rad Laboratories).
The levels of ERa, PgR and SDF-1 transcripts were
determined using real-time quantitative PCR. The pri-
mer sequences are as follows (sense and antisense,
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AGGAGGTGAAGGCAGTGG-3’; and ERa, 5’-GGCA
TGGTGGAGATCTTCGA-3’, 5’-CCTCTCCCTGCA-
GATTCATCA-3’, Actin, 5 ’- TGA GCG CGG CTA
CAG CTT -3’, 5’-CCTTAATGTCACACACGATT-3’.
The PCR reaction was carried out as follows: step 1:
95°C 3 minutes; step 2: for 40 cycles 95°C 20 seconds,
60°C 1 minute; step 3: 70°C 10 seconds, held at 4°C.
Each reaction tube contained: 12.5 μL 2 × SYBR Green
supermix + 6.5 μL nuclease-free water + 1 μL 0.1 μg/
μL primer (pair) + 5 μL cDNA (0.2 μg/μL). Genes
were amplified in triplicate. Data were analyzed by
comparing relative target gene expression to actin con-
trol. Relative gene expression was analyzed using
2-ΔΔCt method [21].
Western blot
MCF-7-control or MCF-7-TamR cells were seeded in
10 cm2 plates at a density of 60 to 70% confluence (5 to
10 × 106 cells) and were allowed to grow for three days
until they approached 80 to 90% confluence. The media
was then removed and the cells were scraped into 1 mL
of PBS plus 3 mM EDTA. The cell suspensions were
spun for five minutes at 2,000 × g and the supernatant
was aspirated. The cell pellets were lysed by vortexing in
200 μL of M-PER mammalian protein extraction buffer
(Pierce, cat. # 78501) containing protease and phospha-
tase inhibitors (Sigma, cat. #’s P1860-1ML, P0044, and
P5726). The samples were then spun in a microcentrifuge
for five minutes at 12,000 × g and the supernatants were
collected. Protein concentrations were determined using
a nanodrop spectrophotometer (Thermo Life Sciences)
and 50 μg of total protein was loaded and run on a 4 to
12% polyacrylamide gel (Invitrogen). The gels were
blotted onto nitrocellulose using the iblot transfer system
(Invitrogen). The blots were blocked for one hour at
room temperature in 1 × TBST (Affymetrix, Santa Clara,
CA, USA, cat # 77500 5 LT) containing 5% non-fat milk.
The blots were then washed in 1 × TBST and were incu-
bated overnight at 4°C in 10 mL of primary antibody at a
1:500 dilution in 5% BSA/TBST (Sigma cat # A7906-1
KG). Blots were then washed in 1 × TBST and incubated
with infrared-labeled secondary antibodies (LiCor) for
30 minutes at room temperature. The blots were then
washed in 1 × TBST and scanned using the Odyssey
infrared imaging system (LiCor, Lincoln, NE USA).
Bands were quantified using the Odyssey software
(LiCor) and normalized to bands corresponding to the
housekeeping Rho-GDI protein. Four independent sam-
ples were prepared for each cell line. Paired t test ana-
lyses were performed for each protein using Origin 8.5.1
software (control vs TamR), and P-values < 0.05 were
considered significant.
Transwell migration assay
Migration assays were performed following the manufac-
turer’s instructions (BD Falcon, Sparks, MD, USA). Briefly,
MCF-7-control or MCF-7-TamR cells were seeded at a
density of 2.5 × 104 in 500 μL serum-free and phenol red-
free media in the upper chamber of a 24-well transwell
system. Phenol red-free DMEM supplemented with FBS
(5%) was used as a chemoattractant in the lower wells.
After 24 h, membranes were scrubbed, fixed with 10%
phospho-buffered formalin, permeabilized with 100% ice-
cold methanol, and stained with 0.1% crystal violet in 20%
methanol. Membranes were removed and mounted on
glass slides for visualization by light microscopy. Data are
represented as a percent of the migrated MCF-TamR cells
per 100 × field of view (100×) ± SEM for triplicate
experiments.
MCF-7 cells overexpressing S100P
Construction of S100P lentiviral vector
The S100P gene was generated by elongating RT-PCR
using a Superscript III one-step RT-PCR system (Invitro-
gen) with the following primers: S100P-F (sense) 5’-CGC
CAC CAT GAC GGA ACT AGA GAC AGC C-3’ and
S100P-R (antisense) 5’-GGA TCC TCA TTT GAG TCC
TGC CTT CTC-3’. The RT-PCR reaction was carried out
as follows: step 1: 45°C for 30 minutes and 94°C for 2 min-
utes; step 2: 35 cycles at 94°C for 15 sec, 51°C for 30 sec
and 72°C for 1 minute; step 3: 72°C for 5 minutes and
held at 4°C. The PCR product was cloned using a TA
Cloning kit (Invitrogen). The S100P lentiviral vector
(pLenti6/S100P) was constructed by digesting vector
pLenti6 (Invitrogen) with EcoR I and BamH I for insertion
of the S100P gene.
MCF-7-S100P cell line stably overexpressing S100P
To produce S100P-overexpressing lentivirus, the 293FT
cells were co-transfected with expression construct
(pLenti6/S100P) and the optimized packaging mix (Vira-
Power Packaging mix, Invitrogen) from a lentiviral expres-
sion system (Invitrogen). The transfection was carried out
by incubating cells overnight at 37°C in a CO2 incubator
using a Lipofectamine 2000 reagent (Invitrogen). Media
were replaced in 24 hours and the virus-containing super-
natants were harvested and centrifuged at 48 to 72 hours.
MCF-7 cells were grown to 30 to 50% confluent, and the
culture medium was replaced with viral supernatants as
obtained previously. Polybrene was added for the over-
night viral transfection. Subsequently, medium was
replaced every 2 to 3 days with antibiotic (Blasticidin) and
the selection process continued for a total of 10 to
12 days. The stable MCF-7-S100P cell line was cultured in
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phenol red free DMEM medium with 5% FBS, and the
S100P expression was checked with Western blot.
Bioinformatics and statistics
Bioinformatics were performed on significantly altered
proteins. This was determined by two parameters: one is
having an analytical replication P-value of < 0.05 and the
second is determined by the ratio value. The standard
deviation (SD) of all the ratios in the control sample was
determined and then significance was defined as (1 +/-
2SD) [22-24]. Classification of proteins was determined
by the web program PANTHER [25]. The proteins were
analyzed for over expression of gene ontology terms in
the categories of pathways, molecular function and biolo-
gical process. Pathway mapping was done using Pathvisio
2.0.11, a tool for visualizing and editing biological path-
ways [26]. The ratio data of the significant proteins were
loaded into Pathvisio and used to map onto preloaded
pathways from Wikipathways [27] and KEGG [28-30].
The pathway thus created was heavily modified from
KEGG pathway 04810, “Regulation of actin cytoskeleton”
in Homo sapiens.
Patient survival analysis
An online database [31] was used to assess relevance of
significantly changed protein expressions to relapse-free
survival. The database was established using gene expres-
sion data and survival information on 1,809 patients
downloaded from Gene Expression Omnibus (GEO)
(Affymetrix HGU133A and HGU133+2 microarrays,
Santa Clara, CA, USA). Briefly, single or multiple genes
were entered into the database to obtain Kaplan-Meier
survival plot where the number-at-risk was indicated
below the main plot. Hazard ratio (and 95% confidence
intervals) and logrank P were calculated and displayed on
the webpage. For the genes listed in Tables 1 and 2, their
effects on relapse-free survival (RFS) were calculated and
listed. Positive logrank P-values indicate positive correla-
tion (that is, either overexpression or down-regulation of
a gene correlates with decreased survival) and negative
logrank P-values indicate negative correlation (that is,
either up- or down-regulation of a gene is associated
with increased survival).
Results
Establishment of 4-hydroxytamoxifen resistant cell line,
MCF-7-TamR
Cell growth assays were performed to determine the
acquired resistance of MCF-7 cells in response to continu-
ous exposure to 4-hydroxytamoxifen over a period of six
months. Initially, MCF-7 cells showed greater than 50%
growth inhibition with tamoxifen treatment as measured
by survival ratio. As shown in Figure 1A, the survival ratio
of the tamoxifen-treated MCF-7 cells was approximately
45%. By the end of the first month, the ratio reached 75%.
The survival ratio increased further to 90% by the end of
month 2, indicating that tamoxifen-treated cells have
resumed the growth rate comparable to untreated condi-
tions. The survival ratio of the tamoxifen treated cell line
remained at about 90% from month 3 and beyond.
The acquired resistance to tamoxifen was further mea-
sured by dose-dependent growth assays (Figure 1B). When
both MCF-7-control and MCF-7-TamR cells were treated
with 4-OH Tam at increasing concentrations from 10-7 M
to 10-5 M, the survival ratios showed marked differences
between the two cell lines. For instance, at 100 nM 4-OH
Tam, MCF-7-TamR cells maintained a 90% survival ratio,
compared to 60% for the tamoxifen sensitive MCF-7-con-
trol cells. At 4 μM, the ratio dramatically decreased to
30% for the control cells but remained around 70% for
MCF-7-TamR. This trend continued until 4-OH Tam
concentration reached 10 μM where no cells survived
from either cell line (Figure 1B).
To further investigate the proliferative behavior of the
resistant cell line clonogenic assays were also performed.
MCF-7-control and MCF-7-TamR cells were each treated
with vehicle (DMSO) or 100 nM 4-OH Tam. The prolif-
eration of tamoxifen sensitive MCF-7 cells was signifi-
cantly inhibited in the presence of 100 nM 4-OH Tam
(approximately 400 colonies compared to 720 in DMSO,
Figure 2A). In contrast, the MCF-7-TamR cells demon-
strated strong resistance to 4-OH Tam induced inhibition
of colony formation. Shown in Figure 2B is a representa-
tive image of colony formation of the two cell lines treated
with vehicle (DMSO) and 4-OH Tam, respectively.
Proteomics data reveal extensive changes in expression
associated with acquired tamoxifen resistance
To increase the total number of proteins that can be
identified and quantified in whole cell lysates, we used a
gel-free approach that relies on isobaric mass tag labeling
for quantitative analysis and a combination of two-
dimensional HPLC separation and high resolution mass
spectrometry for maximal peptide detection and identifi-
cation. Indeed, this approach yielded a total of 2,128
identified and 2,088 quantified proteins, which represent
five to six times more proteins than were analyzed by a
2D-gel based approach used in our previous study [32].
Of these proteins, over 1,200 were found to have statisti-
cally significant changes (P < 0.05) in expression in the
tamoxifen resistant cell line (Additional file 1 Table S1).
While this number appears high, it reflects the high con-
fidence in the analytical reproducibility because the
P-values were calculated from the three isobaric labels as
analytical replicates for each cell line sample. Thus, some
of the smaller fold changes in protein expression, while
statistically significant and accurately reflective of the
Zhou et al. Breast Cancer Research 2012, 14:R45
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Relapse free survival analysis
(Logrank P)
IPI00025311 584 61.7 Breast carcinoma-amplified sequence 1 bcas1 11.28 1.3E-06 -3.2E-5
IPI00017526 95 10.4 Protein S100-P s100p 5.20 2.3E-08 1.7E-6
IPI00218831 218 25.7 Glutathione S-transferase Mu 1 gstm1 3.70 8.6E-07 -3.8E-11
IPI00183695 97 11.2 Protein S100-A10 s100a10 3.15 1.0E-07 2.3E-5
IPI00922108 1002 111.1 Integrin alpha-V itgav 2.88 7.8E-06 2.0E-9
IPI00021267 976 108.2 Ephrin type-A receptor 2 epha2 2.81 3.1E-05 -2.0E-9
IPI00027341 348 38.5 Macrophage-capping protein capg 2.80 2.3E-07 3.9E-5
IPI00106687 222 25.7 Latexin lxn 2.69 1.3E-05 0.2
IPI00013895 105 11.7 Protein S100-A11 s100a11 2.51 3.0E-05 5.1E-10
IPI00455315 339 38.6 Annexin A2 anxa2 2.41 2.7E-08 0.93
IPI00297910 323 35.7 Tumor-associated calcium signal transducer 2 tacstd2 2.19 1.1E-06 0.53
IPI00903145 583 68.5 Radixin rdx 2.17 2.4E-06 0.25
IPI00219301 332 31.5 Myristoylated alanine-rich C-kinase substrate marcks 2.14 6.9E-06 -0.17
IPI00853146 167 19.2 Caveolin cav 2.08 1.0E-03 -4.2E-8
IPI00215995 1051 116.5 Integrin alpha-3 itga3 2.00 2.0E-04 -3.9E-9
IPI00010414 329 36.0 PDZ and LIM domain protein 1 pdlim1 1.94 1.8E-06 -0.009
IPI00795633 448 52.3 Clusterin clu 1.88 1.5E-04 -0.02
IPI00010214 104 11.7 Protein S100-A14 s100a14 1.87 2.1E-04 0.96
IPI00465431 250 26.1 Galectin-3 lgals3 1.79 2.5E-06 0.28
IPI00219219 135 14.7 Galectin-1 lgals1 1.78 2.0E-04 0.008
IPI00018364 183 20.5 Ras-related protein Rap-2b rap2b 1.71 7.5E-05 6.7E-6
IPI00016485 394 42.7 Protein phosphatase slingshot homolog 3 ssh3 1.68 1.1E-03 -2.4E-11
IPI00217563 798 88.4 Integrin beta-1 itgb1 1.64 3.8E-08 6.9E-12
IPI00180240 44 5.1 Thymosin beta-4-like protein 3 tmsl3 1.63 3.7E-07 1.7E-5
IPI00641181 195 19.5 MARCKS-related protein marcksl1 1.55 3.6E-06 0.011
IPI00759759 327 37.1 Epidermal growth factor receptor kinase
substrate 8-like protein 2
eps8l2 1.53 2.4E-03 -0.13
IPI00021828 98 11.1 Cystatin-B cstb 1.52 4.2E-04 4.7E-5
IPI00001871 340 36.5 PRKC apoptosis WT1 regulator protein pawr 1.47 1.9E-04 0.23
IPI00843975 586 69.4 Ezrin ezr 1.41 4.0E-04 1.8E-5
IPI00847442 92 10.1 FK506 binding protein12 fkbp12 1.40 1.4E-05 0.0011
IPI00022462 760 84.8 Transferrin receptor protein 1 tfrc 1.40 1.2E-05 0.00049
IPI00005585 124 13.7 Tax1-binding protein 3 tax1bp3 1.39 5.5E-06 6.7E-6
IPI00016179 98 11.5 Protein S100-A13 s100a13 1.39 7.6E-09 0.15
IPI00005202 247 26.2 Membrane-associated progesterone receptor
component 2
pgrmc2 1.38 2.2E-04 3.6E-5
IPI00015148 184 20.8 Ras-related protein Rap-1b rap1b 1.36 5.7E-06 2.3E-5
IPI00291175 1066 116.6 Vinculin vcl 1.35 2.3E-05 -0.11
IPI00375426 323 36.2 Cathepsin H ctsh 1.34 3.6E-04 -0.44
IPI00011285 714 81.8 Calpain-1 catalytic subunit capn1 1.33 6.1E-06 -0.22
IPI00020599 417 48.1 Calreticulin calr 1.31 3.3E-06 0.67
IPI00009342 1657 189.1 Ras GTPase-activating-like protein IQGAP1 iqgap1 1.29 7.9E-07 1.0E-4
IPI00010080 527 58.0 Serine/threonine-protein kinase OSR1 oxsr1 1.28 5.0E-04 0.49
IPI00478231 193 21.8 Transforming protein RhoA rhoa 1.28 4.8E-07 0.016
IPI00012011 166 18.5 Cofilin-1 cfl1 1.28 1.5E-05 -7.9E-8
IPI00025084 268 28.3 Calpain small subunit 1 capn2 1.26 1.4E-05 -1.6E-12
IPI00013808 911 104.8 Alpha-actinin-4 actn4 1.24 1.5E-04 0.64
IPI00000513 821 90.9 E-cadherin cdh1 1.24 6.6E-05 1.5E-7
IPI00220739 195 21.7 Membrane-associated progesterone receptor
component 1
pgrmc1 1.23 1.1E-03 5.7E-7
IPI00028091 418 47.3 Actin-related protein 3 actr3 1.23 4.8E-04 2.4E-14
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relative protein quantities in the two cell lines, may not
be biologically relevant to acquired tamoxifen resistance.
When the minimum fold change value was set at two
times the standard deviation of all protein ratios in the
control sample, the total number of significantly chan-
ged proteins was reduced to 629 with 364 up-regulated
and 265 down-regulated (Additional file 2 Table S2).
Listed in Tables 1 and 2 are proteins selected for either
their large fold changes or perceived relevance to breast
cancer progression and adaptation to anti-estrogen
treatment. Multiple, functionally distinct proteins are
seen dramatically altered in their expression in the resis-
tant cell line. Importantly, ER regulated proteins such as
cathepsin D and trefoil factor1 (TFF1/PS2) were down-
regulated, suggesting that suppression of ER signaling
pathways is characteristic of tamoxifen resistance
in vitro. Down-regulation of cathepsin D and TFF1/PS2
has also been reported in antihormone treated breast
cancer cells [33].
Several of the up-regulated proteins are involved in
the compensatory mechanisms for survival and prolif-
eration in response to the anti-estrogen challenge. For
example, up-regulation of TROP2 suggests increased
survival signaling by activating ERK1/2 mediated cell
cycle progression [34]. Overexpression of the antiapop-
totic protein, CLU in the tamoxifen resistant cells sug-
gests that it plays a role in counteracting the growth
inhibition effects of tamoxifen.
Another group of differentially expressed proteins are
associated with increased cancer cell motility and inva-
siveness, which include EphA2, BCAS1, S100 protein
family members, Rho family members, Ral-A, Rab family
members, Cdc42, MARCKS, Ezrin, Galectins 1 and 3
among others. These proteins are generally up-regulated
and appear to regulate the cytoskeleton dynamics of the
resistant cells leading to a more motile and aggressive
phenotype.
To determine if the observed proteomic changes are
due to acquired tamoxifen resistance or other changes
including passaging the MCF-7 cells for 12 months, a
three-way quantitative proteomic control experiment
was performed in which an early passage #13 (week 12),
mid passage #25 (week 27), and late passage #50 (week
58) MCF-7-control cells are compared. A total of 635
proteins were compared for their relative abundances by
the fold-change ratios with statistical assessment
(P-values) (Additional file 3 Table S3). These data
confirm that there are no significant proteomic altera-
tions within the MCF-7-control cells after a prolonged
period of culture that are comparable to those occurring
in the MCF-7-TamR cells. The relatively small fold
changes in some protein expressions are not associated
with the consistent, statistically significant changes
occurring in the MCF-7-TamR resulting from develop-
ment of resistance to tamoxifen. Overall, these data
demonstrate that the progressive culturing of cells over
a year in tamoxifen results in changes that are distinct
from matched parental cells grown under normal cul-
ture medium conditions.
Proteomic differential expressions are consistent
with those at the transcriptional 2nd el
To investigate whether the changes observed in protein
expression are a result of transcriptional regulation, we
performed quantitative real-time PCR of 20 differentially
expressed proteins. Because expression levels of mRNA do
not always parallel those of the proteins due to additional
regulatory processes, such as post-transcriptional modifi-
cations, we sought to first validate the proteomic findings
at the transcriptional level. As shown in Figure 3, changes
in mRNA expression are consistent with proteomic fold
changes. For example, the most prominently up-regulated
gene, S100P (180-fold), was also one of the most signifi-
cantly overexpressed proteins (5.2-fold). EphA2, a receptor
tyrosine kinase that was overexpressed by nearly 3-fold in
MCF-7-TamR, was up-regulated by 19-fold at the tran-
scription level. Quantitative RT-PCR also confirmed the
transcriptional down-regulation of several proteins whose
concentrations were significantly decreased (for example,
CA2, CTSD, starD10). Importantly, these results indicate
that as a stable, tamoxifen resistant cell line, MCF-7-
TamR has incurred extensive alterations in the proteome,
and that these changes are paralleled at the transcriptional
level.
Western blots confirm proteomics fold changes
Recent advancement in proteomic techniques has made
quantitative analysis of protein expression an ideal discov-
ery tool with unprecedented reliability and breadth of
scope. The multiple-channel labeling approach combined
with high resolution mass spectrometry employed in this
study provided an additional level of confidence and repro-
ducibility to the proteomic results. However, when targets
are narrowed down to individual functionally relevant
Table 1 Selected up-regulated proteins in tamoxifen resistant breast cancer cells (Continued)
IPI00217519 206 23.6 Ras-related protein Ral-A rala 1.21 3.6E-03 < 1.0E-16
IPI00922213 1014 111.2 fibronectin 1 fn1 1.19 3.4E-02 0.46
IPI00220847 1745 194.3 Integrin beta-4 itgb4 1.19 6.3E-04 -0.12
IPI00016786 191 21.2 Cell division control protein 42 homolog cdc42 1.15 5.2E-05 -4.3E-10
Zhou et al. Breast Cancer Research 2012, 14:R45
http://breast-cancer-research.com/content/14/2/R45
Page 8 of 21
proteins, Western blotting offers a more specific and effi-
cient method of validation as long as antibodies are avail-
able. To this end, we sought to confirm our proteomic
findings of some of the most significant targets by Western
blot. Semi-quantitative Western blot analysis of the MCF-
7-control and MCF-7-TamR cells was done for total pro-
tein levels of EphA2, S100P, TROP-2, StarD10 and
MARCKS, all of which may be involved in the develop-
ment of tamoxifen resistance. Results in Figure 4A, B show
a statistically significant increase in the expression levels of
EphA2 (approximately two-fold), S100P (approximately
eight-fold), MARCKS (approximately three-fold), and
TROP-2 (approximately three-fold) and a decrease in
StarD10 (approximately two-fold) levels, confirming the
differential expressions determined in both proteomic ana-
lysis and RT-PCR results.
Because proteomic analysis did not detect the presence
and alterations of many receptors of key interests, includ-
ing the tamoxifen target ER, we also performed Western
blots to determine the status of ERa in the resistant cell
line. Immunostaining clearly showed a marked decrease
in total ERa protein level in the resistant cell line (> 20-
fold), confirming that in the tamoxifen resistant MCF-7
cells obtained in our laboratory, ERa is significantly
down-regulated but not lost (Figure 4A, B).
ER regulated signaling pathways are suppressed but
remain functional in MCF-7-TamR cells
The observation of reduced expression of ERa in the
resistant MCF-7 cells prompted us to ask whether ER
regulated signaling is suppressed and, if so, whether ER
remains functional. We first investigated the expression










Relapse free survival analysis
(Logrank P)
IPI00218414 260 29.2 Carbonic anhydrase 2 ca2 -2.70 1.3E-05 0.79
IPI00032808 219 24.3 Ras-related protein Rab-3D rab3d -2.36 4.5E-06 1.2E-4
IPI00472076 175 19.4 tumor protein D53 tpd52l1 -2.03 7.5E-06 0.66
IPI00012866 480 55.7 RAC-alpha serine/threonine-protein
kinase
akt1 -1.95 3.4E-06 -0.028
IPI00647268 189 21.6 Ras homolog gene family, member C rhoc -1.86 6.4E-06 -0.019
IPI00025318 114 12.8 SH3 domain-binding glutamic acid-
rich-like protein
sh3bgrl -1.75 2.4E-05 3.8E-5
IPI00550020 102 11.5 Parathymosin ptms -1.74 5.2E-06 0.095
IPI00186008 291 33.0 PCTP-like protein stard10 -1.74 9.7E-04 NA
IPI00011564 198 21.6 Syndecan-4 sdc4 -1.68 2.1E-04 NA
IPI00019502 1960 226.4 Myosin-9 myh9 -1.63 5.8E-06 -0.085
IPI00011696 845 98.3 Proto-oncogene vav vav1 -1.58 4.8E-02 6.2E-11
IPI00022283 84 9.1 Trefoil factor 1 tff1 -1.54 1.5E-04 1.5E-5
IPI00550900 172 19.6 Translationally-controlled tumor protein tpt1 -1.51 1.4E-06 1.1E-10
IPI00019345 184 21.0 Ras-related protein Rap-1A rap1a -1.50 1.2E-05 -9.5E-8
IPI00479997 149 17.3 Stathmin stmn1 -1.47 1.5E-05 -2.9E-12
IPI00011229 412 44.5 Cathepsin D ctsd -1.45 5.9E-07 0.56
IPI00216319 246 28.2 14-3-3 protein eta ywhah -1.45 5.5E-04 -0.066
IPI00217975 586 66.4 Lamin-B1 lmnb1 -1.43 2.3E-05 0.32
IPI00414676 724 83.2 Heat shock protein HSP 90-beta hsp90ab1 -1.40 5.9E-07 5.6E-7
IPI00246975 225 26.5 Glutathione S-transferase Mu 3 gstm3 -1.37 8.9E-07 0.008
IPI00009607 183 20.7 Ras-related protein Rap-2c rap2c -1.36 2.4E-03 -3.1E-6
IPI00020904 358 40.9 Serine/threonine-protein kinase PRKX prkx -1.33 6.5E-03 0.7
IPI00000041 196 22.1 Rho-related GTP-binding protein RhoB rhob -1.33 2.0E-03 0.0032
IPI00003815 204 23.2 Rho GDP-dissociation inhibitor 1 arhgdia -1.27 1.5E-03 0.0042
IPI00955014 297 34.1 cell division control protein 2 homolog cdk1 -1.26 6.1E-04 NA
IPI00419235 229 26.9 Glutathione S-transferase Mu 5 gstm5 -1.25 1.3E-04 < 1E-16
IPI00941907 350 38.4 Serine-threonine kinase receptor-
associated protein
strap -1.25 1.7E-05 -5.4E-9
IPI00297261 435 49.9 Tyrosine-protein phosphatase non-
receptor type 1
ptpn1 -1.25 4.3E-04 1.1E-11
IPI00019812 499 56.8 Serine/threonine-protein phosphatase 5 ppp5c -1.15 4.4E-04 7.4E-12
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of two ER regulated genes, PgR and SDF-1 in MCF-7-
TamR and MCF-7-control cells (Figure 5A). Both PgR
and SDF-1 were dramatically down-regulated in resis-
tant cells when compared to DMSO treated control
cells. For reference the ER gene expression was also
determined by RT-PCR and was found to be greatly
suppressed in the resistant cell line as its mRNA level
was less than 10% that of the control. In MCF-7-control
cells, treatment with E2 induced a three-fold increase in
PgR mRNA level (Figure 5A). However, in the resistant
cells, while the PgR level was low, E2 stimulation still
caused a dramatic increase of PgR expression (Figure
5B). This observation indicated that ER remained func-
tional in tamoxifen-resistant MCF-7 cells, albeit to a
much diminished extent. Similarly, the mRNA expres-
sion of SDF-1, an ER dependent gene was seen signifi-
cantly down-regulated in MCF-7-TamR cells compared
to the control cells (Figure 5A). Upon treatment with
E2, SDF-1 expression went up over two-fold, again sug-
gesting that ER dependent signaling pathways remained
functional after long term exposure to the anti-estrogen
(Figure 5B).
Pathway analysis reveals that actin cytoskeleton
regulation drives enhanced cell motility in TamR cells
Gene ontology analysis using PANTHER [25] indicates
that the significantly changed proteins constitute an over
representation of “Cytoskeletal regulation by Rho GTPase
pathway” (P < 0.0001) and “Integrin signaling pathway”
(P < 0.0001) (Additional file 4 Figure S4). To understand
the molecular signaling associated with these proteomic
changes in the tamoxifen resistant cells we mapped our
protein changes on a custom pathway derived from an ori-
ginal KEGG pathway framework (See Experimental sec-
tion). Twenty-four proteins from our proteomic data were
identified as involved in the regulation of cell motility, of
which 21 showed statistically significant changes in
expression levels (ACTB, ARP2/3, c-Src, CAPN1, CFL1,
CRKL, DIAPH1, EphA2, EZR FN1, GNA13, IQGAP,














































Figure 1 Treatment of MCF-7 cells with 4-OH Tam resulted in a resistant phenotype. A. Survival ratio vs time (zero to six months). MCF-7
cells cultured with 10-7 M 4-OH tamoxifen for zero to six months were plated in six-well plates at a density of 50,000 per well in 5% FBS DMEM
medium. The cells were counted after treatment with 10-7 M 4-OH tamoxifen for five days; the final concentration of ethanol was 0.1%. B.
Survival ratio vs 4-hydroxytamoxifen concentration. MCF-7 cells cultured for six months with 10-7 M 4-OH tamoxifen (MCF-7-TamR) and 0.1%
ethanol (MCF-7-control) were seeded in 96-well plates at a density of 3,000 each in 5% FBS phenol-red free DMEM medium. The cells were then
treated with 10-7 to 10-5 M 4-OH tamoxifen for five days.
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VCL). Figure 6 illustrates a reconstructed KEGG pathway
map of actin cytoskeleton regulation. In one possible sce-
nario, enhanced Rho-Rock signaling is enabled by
increased expression of G-alpha 13 (GNA13) [35,36] and
by EphA2-induced suppression of p190 RhoGap [37,38]
(Figure 6, orange lines). In another signaling route
depicted in the map, increased integrin-beta1 (ITGB)
expression is implicated in the formation of focal
adhesions with adaptor proteins talin, vinculin (VCL), acti-
nin, filamin and other associated proteins such as vasodila-
tor-stimulated phosphoprotein (VASP) [39]. This complex
of integrins and proteins then binds to a-actin and f-actin
through the Arp 2/3 complex. Up-regulation of several of
these components indicate that the tamoxifen resistant
cells are experiencing an increase of integrin mediated
actin cytoskeleton regulation (Figure 6, green lines).


























Figure 2 MCF-7-TamR cells are resistant to tamoxifen in clonogenic assays. A. Effect of tamoxifen on colony formation of MCF-7-TamR and
MCF-7-control. Number of colonies formed in resistant and sensitive cell lines was plotted as a function of treatment (DMSO and tamoxifen). B.
Representative colony images of the resistant and sensitive cells.
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MCF-7-TamR cells exhibit enhanced motility
The KEGG pathway analysis based on the proteomic
data indicates that up-regulation of cytoskeleton related
pathways may facilitate migration of MCF-7-TamR cells.
To confirm this, we carried out transwell migration
assays. When MCF-7-control and MCF-7-TamR cells
were seeded at a density of 2.5 × 104 in media free of
serum and phenol red, the tamoxifen resistant cells
were found to migrate faster than the tamoxifen sensi-
tive control cells. As shown in Figure 7, MCF-7-TamR
cell demonstrated increased basal migration by eight-
fold (100% migration compared to 13% for MCF-7-
control cells). This result suggests that tamoxifen resis-
tance is associated with enhanced cell motility, consis-
tent with previous reports that antiestrogens promote
breast cancer motility and invasion [12,40,41].
S100P plays an important role in acquired tamoxifen
resistance and enhanced cell motility
We next sought to investigate the role of S100P, a signifi-
cantly up-regulated protein in MCF-7-TamR cells in con-
ferring tamoxifen resistance and increased migration. As
shown in Figure 8A, since the parental MCF-7 cell line
expresses negligible level of S100P compared to the resis-
tant cells, we decided to overexpress it in MCF-7 cells by
a lentiviral transduction of the S100P gene. The resulting
MCF-7-S100P cells exhibited a dramatic increase in
S100P expression (Figure 8A). Subsequent survival assays
demonstrated that stable overexpression of S100P in
MCF-7 cells enhanced their resistance to tamoxifen
when compared to the control. As illustrated in Figure
8B, after treatment with 4-OH Tam for five days at 10-7
M, the survival ratio of MCF-7-S100P cells was signifi-
cantly higher than the control MCF-7 cells (80% vs 60%,
P < 0.001). The effect of S100P up-regulation on MCF-7
cell motility was also investigated by transwell migration
assays. In Figure 8C, MCF-7 cells stably overexpressing
S100P demonstrated over 60% (P < 0.05) increase in
migratory capacity compared to the MCF-7-control cells.
Survival analysis reveals relevance of many altered
proteins to breast cancer prognosis
To assess the relevance of the altered expression levels of
various proteins on the clinical outcome in breast cancer
patients, we performed survival analysis of up- and
down-regulated proteins selected in Tables 1 and 2 using
an online survival analysis tool. The online database con-
tains the expression of 22,277 genes and survival infor-
mation of 1,809 patients [31]. As shown in the last
columns of Tables 1 and 2, alterations in the expression
level of many proteins in tamoxifen resistant cells were
found to positively correlate with decreased survival. For
example, the up-regulation of S100P, S100A10, S100A11,
integrin alpha-V (itgav), macrophage-capping protein
(capg), ezrin and RhoA appear to be predictive of poor
survival (Table 1). On the other hand, down-regulation
of a number of proteins such as proto-oncogene vav
(vav1), trefoil factor 1 (tff1/PS2), translationally-con-
trolled tumor protein (tpt1), glutathione S-transferase
























Figure 3 Quantitative RT-PCR confirms that mRNA levels are consistent with protein expressions for the selected genes.
Zhou et al. Breast Cancer Research 2012, 14:R45
http://breast-cancer-research.com/content/14/2/R45
Page 12 of 21
type 1 (ptpn1), and heat shock protein HSP 90-beta
(hsp90ab1), are also significantly correlated to poor prog-
nosis and decreased survival. However, tamoxifen resis-
tance appears to induce expression changes of numerous
proteins that are associated with improved survival in
clinical results. For instance, the overexpression of breast
carcinoma-amplified sequence 1 (bcas1), glutathione S-
transferase Mu 1 (gstm1), ephrin A2 receptor (epha2),
caveolin (cav), calpain small subunit 1 (capn2) and the
down-regulation of stathmin (stmn1), serine-threonine
kinase receptor-associated protein (strap), Ras-related
protein Rap-1A (rap1a) all point to a better prognosis as
indicated by the Kaplan-Meier survival curves (see nega-
tive long-rank P-values in the last columns of Tables 1
and 2).
Figure 9A-D represents the Kaplan-Meier survival
plots for S100P gene using two different survival options
(Figure 9A, C) and two patient cohorts (Figure 9B, D).
Up-regulation of S100P is correlated to reduced survival
over a period of 20 years for both relapse free survival
(P = 1.7e-6) and distant metastasis free survival (P =
0.029). For systematically untreated patients, overexpres-
sion of S100P gene is again predictive of lower relapse
free survival rate (P = 0.017) but not statistically signifi-
cant for prognosis of distant metastasis free survival
(P = 0.18). Shown in Figure 9E, F are Kaplan-Meier sur-
vival curves where breast cancer subtyping is used based
on ER status. For the ER (+) subgroup, overexpression
of S100P is significantly associated with decreased survi-
val (Figure 9E, P = 0.00037). However, this correlation is
lost with ER(-) breast cancer patients (Figure 9F, P =
0.95), suggesting that S100P is not a useful predictor in
hormone independent breast cancer subtypes. In addi-
tion, we found that the prognostic value of S100P in the
available data set for ER+ endocrine treated patients
(Figure 9G, H) was not significant.
Discussion
We have established a tamoxifen-resistant breast cancer
cell line obtained under an FBS-containing medium condi-
tion to minimize adaptive cellular changes in response to
LTED. Indeed, earlier studies have shown that LTED leads
to enhanced expression of the estrogen receptor [42] or
EGFR [14], which are not usually observed in tamoxifen
resistant cell lines cultured in normal FBS medium
[13,15]. In the MCF-7-TamR cell line obtained in this
study after six months of 4-OH tamoxifen treatment, the
estrogen receptor was significantly down-regulated but
retained viable function (Figure 5). Current understanding
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Figure 4 Western blot analysis confirms protein changes in MCF-7-TamR cells initially identified in quantitative proteomics. A) A
representative Western blot of control (con) and tamoxifen resistant (MCF-7-TamR) cells showing the different expression levels of the indicated
proteins. B) Four independent samples from each cell line were used to quantify the levels of each protein. The housekeeping protein Rho-GDI
was used as an internal loading control. For comparative purposes, the control samples were set to 100%.
Zhou et al. Breast Cancer Research 2012, 14:R45
http://breast-cancer-research.com/content/14/2/R45
Page 13 of 21
process in response to anti-estrogen challenge where
breast cancer cells evolve from an estrogen-dependent
phenotype to a non-responsive one and eventually to a
stage of estrogen independence. Our results indicate the
tamoxifen resistant cells appear to be at a stage of mini-
mized estrogen responsiveness without complete loss of
ER. Previous studies of tamoxifen resistance using in vitro
models suggest translocation of ER from nucleus to mem-
brane, facilitating crosstalk with growth factor receptors
and enhancing the non-genomic signaling of the ER. In
these reports, the total ER levels remain largely unchanged
[13,15,42]. On the other hand, complete loss of ER expres-
sion has occurred when MCF-7 cells became resistant to
the pure antiestrogen, fulvestrant [43-45].
This in vitro behavior is also consistent with clinical
observations that tamoxifen resistant tumors may still
respond to fulvestrant [46,47] and that only 15 to 30% of
patients present with complete loss of ER at time of relapse
[11,48,49]. The down-regulation of ER mediated signaling
pathways in our MCF-7-TamR cells is corroborated by
proteomic evidence that showed suppressed expression
levels of cathepsin D and TFF1/PS2 and was confirmed by
Western blot analysis showing diminished ER protein
expression. PgR, an ER dependent gene, was also found
significantly down-regulated (> 1,000-fold, Figure 5A) by
RT-PCR analysis. On the other hand, E2 stimulation did
induce a 50-fold increase in PgR expression from its greatly
suppressed basal level (Figure 5B) in the resistant cells.
A 
B 
Figure 5 MCF-7-TamR cells exhibit significantly down-regulated ER mediated signaling pathways. A) MCF-7-control and MCF-7-TamR
cells were grown in 5% phenol free DMEM for 48 hours prior to 24 hours treatment with 1 nM 17b-estradiol (E2) or vehicle control (DMSO). Q
PCR was performed for ER regulated genes ER, PgR, and SDF-1. Normalization was to MCF-7-control cells treated with vehicle; B) E2 induced ER
regulated gene expression for tamoxifen resistant cells (normalization to MCF-7-TAMR treated with DMSO). qPCR was performed for genes ER,
SDF-1, and PgR. Results reflect average fold change in cycle number for mRNA levels +/-. Cycle number was normalized to b-actin. * Significantly
different from DMSO control, P < 0.05.
Zhou et al. Breast Cancer Research 2012, 14:R45
http://breast-cancer-research.com/content/14/2/R45
Page 14 of 21
In ER positive breast cancer cells, estrogen signaling is
the main mediator of proliferation and tumor progres-
sion. Adaptation to tamoxifen challenge which blocks ER
signaling must involve activation of alternative survival
signaling to sustain growth and circumvent the apoptotic
effect of tamoxifen. As demonstrated in numerous in
vitro and in vivo studies on the mechanisms of tamoxifen
resistance, tumor cells recruit a remarkably wide variety
of signaling pathways to achieve the resistant outcome
[50,51], including cross talk with EGFR and Her2 [52,53],
and enhanced nongenomic signaling accompanied by
translocation of ER [54,55]. Our study identified several
proteins that are known to promote tumorigenesis and
progression but their roles in tamoxifen resistance have
not been explored. In particular, the up-regulation of
S100P revealed a previously unknown link between
tamoxifen resistance and the small calcium binding
protein. S100P is a ligand for the receptor for advanced
glycation end product (RAGE). Binding of the Ca2+ acti-
vated S100P homodimer to RAGE has been shown to
promote cancer cell proliferation via the ERK1/2 and
NFB signaling pathways [56-58]. S100P was found to
co-immunoprecipitate with RAGE and its action on cell
survival and proliferation could be blocked by RAGE
inhibitors [56].
The forced overexpression of S100P in the tamoxifen
sensitive MCF-7 cell line increased its resistance to
tamoxifen significantly (Figure 8B), confirming the role
of S100P in acquired tamoxifen resistance. Our results
suggest that, as the ER-regulated proliferation pathway
was severely suppressed after prolonged exposure to
tamoxifen, the S100P-RAGE signaling via activation of
ERK1/2 and possibly NF-B is increased as a compensa-
tory mechanism of cell proliferation and survival.
Figure 6 Regulation of actin cytoskeleton in the tamoxifen resistant cell line, MCF-7-TamR. The pathway illustrates changes to proteins
expression, TamR cell line vs. control, involved in regulating the actin cytoskeleton. All red proteins are significantly up-regulated and all blue
proteins are significantly down-regulated. The ratio value for each significantly regulated protein is indicated to the right. Solid lines with no
arrow indicate physical interaction. Solid lines with an arrow or bar at the end indicate direct activation or inhibition, respectively. Dotted lines
indicate indirect or unknown method of interaction. The orange lines highlight the Rho activation pathways and the green lines highlight
integrin mediated focal adhesions.
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In addition, the up-regulation of the anti-apoptotic
protein CLU can be viewed as another possible survival
pathway contributing to tamoxifen resistance. Previous
reports have implicated CLU up-regulation as a general
defense mechanism of cancer cells toward cytostatic
drugs [59-61]. Under cell stress, such as treatment with
trastuzamab in breast cancer cells, or following andro-
gen ablation in prostate cancer cells, significant increase
in CLU expression was associated with activation of
alternative signaling [62,63].
Another significantly up-regulated protein, EphA2, may
contribute to the survival of tamoxifen resistant cells.
The EphA2 expression level in breast cancer cells has
been found inversely related to ER expression [64,65].
This is consistent with our RT-PCR and Western blot
results where ER was significantly down-regulated (Fig-
ures 4 and 5). EphA2-transfected cells demonstrated
increased growth in vitro and form larger and more
aggressive tumors in vivo [66]. Moreover, EphA2 overex-
pression decreased the ability of tamoxifen to inhibit
breast cancer cell growth and tumorigenesis [67,68]. The
finding in this study that EphA2 was overexpressed in a
tamoxifen resistant cell line confirms the involvement of
the receptor tyrosine kinase in the development of
tamoxifen resistance in breast cancer.
As the cells adapt to the inhibitory effects of tamoxifen,
the acquired resistance appears to transform the breast
cancer cells into a more aggressive phenotype with
increased motility. Indeed, many of the overexpressed
proteins thought to regulate growth and proliferation in
our TamR cells have also been implicated in promoting
cancer cell migration and invasion. Gene Ontology and
KEGG pathway analyses collectively using proteomic
data suggest that regulation of actin cytoskeleton may be
responsible for driving the motility of TamR cells. The
novel role of S100P in the regulation of cytoskeleton
dynamics was highlighted in the pathway map (Figure 6)
in which S100P was involved in the interactions with
ezrin [69], a membrane/F-actin cross-linking protein
implicated in tumor metastasis [70-73], and with the
scaffolding protein IQGAP1 [74], known to promote cell
motility and invasion [75]. To confirm the involvement
of S100P in regulation of tamoxifen induced cell motility,
we conducted functional studies of S100P by overexpres-
sing the protein in the parental MCF-7 cells and observed
increased motility in MCF-7-S100P cells as a result
Figure 7 Acquired resistance to tamoxifen in MCF-7 cells leads to enhanced migration capacity. 2.5 × 104 MCF-7 or MCF-7-TamR cells
were seeded on the upper chamber of a transwell system where the lower wells contained media with 5% serum. After 24 h, cells were fixed
and stained with crystal violet and the number of migrated cells counted. Bars represent the percent of migrated MCF-TamR cells per 100 ×
field of view ± SEM. ***, P < 0.001.
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(Figure 8C). Moreover, our proteomic finding that both
ezrin and IQGAP1 were up-regulated in the tamoxifen
resistant cells (1.43- and 1.29-fold, respectively) provided
additional evidence for the involvement of S100P in
motility enhancement and suggests that the mechanism
of action may involve the ezrin and IQGAP1 pathways.
Finally, overexpression of S100P and its role in med-
iating tamoxifen resistance and cell motility also bear
clinical relevance. Using a GEO gene expression data-
base from 1,809 breast cancer patients, the Kaplan-
Meier survival plots demonstrate the prognostic rele-
vance of S100P overexpression on patient survival.
Overexpression of S100P is predictive of lower relapse
free survival (P = 1.76e-6) and significantly correlated
with decreased distant metastasis free survival (P =
0.029). Furthermore, truly prognostic patient group, that
is, systematically untreated breast cancer patients with
higher levels of S100P tend to have shorter relapse free
period (P = 0.017). Finally, S100P up-regulation appears
to be significantly associated with reduced survival in
ER(+) but not in ER(-) breast cancer patients.
Conclusion
Using a quantitative proteomic approach we have identi-
fied and verified key adaptive protein changes that are
involved in the development of tamoxifen resistance. Long
term treatment with 4-hydroxytamoxifen significantly sup-
pressed ER-regulated signaling pathways in MCF-7 breast
cancer cells. This was demonstrated in the marked down-
regulation of ER dependent genes, including PgR, PS2, and
SDF-1. In response, alternative survival signaling was acti-













































Figure 8 S100P up-regulation in MCF-7 cells confers tamoxifen resistance and enhanced migration. A) Western blot of S100P expression
in MCF-7, MCF-7-TamR, MCF-7-S100P. B) Survival ratio of MCF-7, MCF-7-TamR, MCF-7-S100P after treatment of 4-hydroxytamoxifen for five days.
C) Migration assay for MCF-7, MCF-7-TamR, MCF-7-S100P.
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Figure 9 Kaplan-Meier survival plots demonstrate the prognostic relevance of S100P overexpression on patient survival. A)
Overexpression of S100P is predictive of lower relapse free survival (P = 1.76e-6) for all patients; B) overexpression of S100P is correlated with
decreased distant metastasis free survival (P = 0.029); C) Untreated breast cancer patients had lower relapse free survival if their tumors
overexpressed S100P (P = 0.017); D) Weak correlation between the metastasis free survival and overexpression of S100P (P = 0.18); E) Higher
level of S100P expression is predictive of poor relapse free survival for ER positive breast cancer patients (P = 0.00037); F) S100 overexpression is
not associated with survival of ER negative breast cancer patients; G) S100 overexpression is not statistically significant for prognosis of ER
positive endocrine treated patients; H) Overexpression of S100P is not predictive of metastasis-free survival of ER positive endocrine treated
patients.
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multiple proteins. This was reflected in the global proteo-
mic changes that included the increased expression of
TROP2, CLU, MARCKS, and S100 family proteins. In par-
ticular, we identified S100P, an EF-hand calcium binding
protein previously implicated in breast and other solid
tumors, as a significant player in conferring tamoxifen
resistance and cell motility. Overexpression of S100P in
the hormone sensitive parental MCF-7 cells significantly
increased resistance to tamoxifen. The mechanism of
S100P action may involve its interaction with the receptor
RAGE, leading to sustained survival and proliferation.
Proteomic analysis of MCF-7-TamR cells also revealed
a critical phenotypic transformation of the cells towards
an increased migratory capacity, consistent with most
clinical outcomes where tumor invasion and metastasis
follow the acquired hormone resistance in patients. The
enhanced cell motility in the tamoxifen resistant cells
appeared to be driven by the cytoskeletal dynamics where
S100P played an important role. This was supported by
the observation that overexpressing S100P in MCF-7
cells significantly increased cell migration. Additional evi-
dence comes from proteomic data where up-regulation of
multiple proteins in a coordinated signaling network may
regulate the actin cytoskeleton dynamics as depicted in
our proposed pathway model. Specifically, we observed
the up-regulation of EphA2, RhoA, ITGB1, vinculin,
ezrin, and radixin, which are key proteins contributing to
the increased cell motility in a tamoxifen resistant pheno-
type by promoting actin fiber polymerization, filopodia
formation, and cell contractability.
Additional material
Additional file 1: (Table S1). List of all proteins identified in global
proteomic analysis. The file contains 2,128 proteins that were identified
and 2,088 proteins quantified, with IPI number, protein description, fold
change and statistical P-value where applicable.
Additional file 2: (Table S2). List of significantly altered proteins
from proteomic anlaysis. This file contains 629 significantly changed
proteins as defined in the Results section where the significant fold
change of proteins was defined as greater than two times standard
deviation and P < 0.05.
Additional file 3: (Table S3). List of proteins identified and
quantified in three MCF-7-control cell samples obtained at different
passages. This file contains a total of 635 proteins with relative
abundances by the fold-change ratios with statistical assessment (P-
values).
Additional file 4: (Figure S4). Gene ontology analysis of significantly
altered proteins reveals overrepresentation of Integrin Signaling
Pathway. This file contains the over or under representation of pathways
determined using the web based program PANTHER http://www.
pantherdb.org and the significantly up- and down-regulated proteins.
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